Why it matters
The removal affects a company that provides pharmaceutical services and may matter to businesses assessing U.S. restrictions on Chinese firms. The supplied reports do not quantify effects on U.S. drug supply or costs.
What happens next
The South China Morning Post says the decision was published in the Federal Register. The reports do not identify further steps or say whether other companies will be removed from the list.
Any further U.S. government changes to the list.
Whether the removal changes restrictions or business activity for WuXi AppTec or its customers.